Comment
doi: 10.1038/s41571-021-00533-w.
Sotorasib effective in KRAS-mutant NSCLC
Affiliations
- PMID: 34140669
- DOI: 10.1038/s41571-021-00533-w
Item in Clipboard
Comment
Sotorasib effective in KRAS-mutant NSCLC
Nat Rev Clin Oncol.
2021 Aug.
No abstract available
Comment on
-
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4. N Engl J Med. 2021. PMID: 34096690 Free PMC article. Clinical Trial.
Similar articles
-
KRAS Inhibitor Resistance in MET-Amplified KRAS G12C Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.Clin Cancer Res. 2021 Oct 15;27(20):5697-5707. doi: 10.1158/1078-0432.CCR-21-0856. Epub 2021 Aug 7. Clin Cancer Res. 2021. PMID: 34365406
-
Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".J Thorac Oncol. 2024 Sep;19(9):e43. doi: 10.1016/j.jtho.2024.06.015. J Thorac Oncol. 2024. PMID: 39242149 No abstract available.
-
A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib".J Thorac Oncol. 2024 Sep;19(9):e44-e45. doi: 10.1016/j.jtho.2024.07.001. J Thorac Oncol. 2024. PMID: 39242150 No abstract available.
-
Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.Drugs Today (Barc). 2022 Apr;58(4):175-185. doi: 10.1358/dot.2022.58.4.3400573. Drugs Today (Barc). 2022. PMID: 35412531 Review.
-
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.Lung Cancer. 2021 Oct;160:152-165. doi: 10.1016/j.lungcan.2021.07.005. Epub 2021 Jul 16. Lung Cancer. 2021. PMID: 34417059 Review.
Cited by
-
Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments.Diagnostics (Basel). 2021 Nov 25;11(12):2196. doi: 10.3390/diagnostics11122196. Diagnostics (Basel). 2021. PMID: 34943432 Free PMC article.
-
Clinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR.Biomedicines. 2021 Jul 28;9(8):906. doi: 10.3390/biomedicines9080906. Biomedicines. 2021. PMID: 34440110 Free PMC article. Review.
-
The complex journey of targeting RAS in oncology.BMC Cancer. 2025 Jul 1;25(1):1053. doi: 10.1186/s12885-025-14033-y. BMC Cancer. 2025. PMID: 40597785 Free PMC article. Review.
-
Design of new drugs for medullary thyroid carcinoma.Front Oncol. 2022 Dec 5;12:993725. doi: 10.3389/fonc.2022.993725. eCollection 2022. Front Oncol. 2022. PMID: 36544713 Free PMC article.
-
Clinical outcomes of KRAS-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: a retrospective observational study.Transl Lung Cancer Res. 2023 Oct 31;12(10):2030-2039. doi: 10.21037/tlcr-23-449. Epub 2023 Oct 27. Transl Lung Cancer Res. 2023. PMID: 38025817 Free PMC article.
References
Original article
-
- Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2103695 (2021) - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
